Children and Adolescent Hodgkin Lymphoma in Argentina: Long-term Results After Combined ABVD and Restricted Radiotherapy

Abstract

The strategy of avoiding RT for LR and IR patients that responded completely to ABVD chemotherapy achieved very good results. For the HR group, the combination of 6 cycles of ABVD and Low-dose involved field radiotherapy was efficacious with similar good results. Nearly half of the patients could be cured without RT.

Pediatric Hodgkin Lymphoma; Experience with Euronet Pediatric Hodgkin Lymphoma Protocol in a Developing Country

“…Faizan et al [7] from Pakistan used same treatment protocol and reported very similar 5-years OS and EFS as 92 % and 84 % respectively. Other studies from developing countries reported similar results [7][8][9][10][12][13][14]19,20]. (Summarized in Table 3).…”

Pediatric Hodgkin Lymphoma, Version 3.2021

“…In some pediatric patients with CHL, the ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) may be considered. [35][36][37][38][39] The panel recommends referring to the NCCN Guidelines for Hodgkin Lymphoma in adults (available at NCCN.org) to review relevant data and context.…”

“…As recommended for low-risk CHL, the ABVD regimen may be considered for some pediatric patients. [35][36][37][38][39] The panel recommends referring to the adult NCCN Guidelines for Hodgkin Lymphoma to review relevant data and context.…”

“…In certain circumstances, BEACOPP and ABVD regimens may be considered for some pediatric patients. [35][36][37][38][39]43 The panel recommends referring to the adult NCCN Guidelines for Hodgkin Lymphoma (available at NCCN.org) to review relevant data and context. It is worth noting that in the NCCN Guidelines for Hodgkin Lymphoma in adults, regimens with reduced numbers of cycles of BEACOPP have been developed.…”

Results of GPOH-HD-2003 study in treatment of Hodgkin’s lymphoma in children and adolescents in the Morozovskaya Children’s Clinical Hospital

“…Количество введений этопозида в каждом курсе увеличилось с 4 до 5 (ОЕРА), таким образом, кумулятивная доза за 2 курса составила 1250 мг/м 2 . Однако это значение осталось ниже критической кумулятивной дозы этопозида в 2000 мг/м 2 , приводящей впо-1 О р и г и н а л ь н ы е и с с л е д о в а н и я || O r i g i n a l s t u d i e s следствии к высокому риску развития вторичного острого миелобластного лейкоза [10,12,13]. В целях исключения прокарбазина курс СОРР был модифицирован в COPDAC с применением дакарбазина.…”